Litigation Details for Genentech, Inc. v. Amgen Inc. (D. Del. 2017)
✉ Email this page to a colleague
Genentech, Inc. v. Amgen Inc. (D. Del. 2017)
Docket | ⤷ Sign Up | Date Filed | 2017-10-06 |
Court | District Court, D. Delaware | Date Terminated | |
Cause | 35:271 Patent Infringement | Assigned To | Gregory Moneta Sleet |
Jury Demand | Plaintiff | Referred To | |
Patents | 8,512,983; 9,441,035 | ||
Link to Docket | External link to docket |
Biologic Drugs cited in Genentech, Inc. v. Amgen Inc.
The biologic drugs covered by the patents cited in this case are ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , and ⤷ Sign Up .
Details for Genentech, Inc. v. Amgen Inc. (D. Del. 2017)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2019-06-17 | 401 | Opinion - Memorandum Opinion | appear in the following patents: U.S. Patent Nos. 8,512,983 ("the '983 patent"); 9,441,035 (…general, however, the '983 patent, '035 patent, and '869 patent relate to various aspects of… 326, 381, 476. The '879 patent, '901 patent, and '269 patent disclose humanized and variant… ("the '035 patent"); 8,574,869 ("the '869 patent"); 6,884,879 ("the…the '879 patent"); 7,169,901 ("the '901 patent"); and 7,060,269 ("the ' | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |